PF 960 in [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine], a new MAO-B inhibitor, attenuates MPTP-induced depletion of striatal dopamine levels in C57/BL6 micePEREZ, Virgili; UNZETA, Mercedes.Neurochemistry international. 2003, Vol 42, Num 3, pp 221-229, issn 0197-0186, 9 p.Article

Chronic treatment of Syrian hamsters with low-dose selegiline increases life span in females but not malesSTOLL, S; HAFNER, U; KRÄNZLIN, B et al.Neurobiology of aging. 1997, Vol 18, Num 2, pp 205-211, issn 0197-4580Article

Selegiline's neuroprotective capacity revisitedRIEDERER, P; LACHENMAYER, L.Journal of neural transmission. 2003, Vol 110, Num 11, pp 1273-1278, issn 0300-9564, 6 p.Article

Urinary excretion of selegiline N-oxide, a new indicator for selegiline administration in manKATAGI, M; TATSUNO, M; TSUTSUMI, H et al.Xenobiotica (London. Print). 2002, Vol 32, Num 9, pp 823-831, issn 0049-8254Article

A trial of L-Deprenyl for the treatment of neuroleptic-induced parkinsonismRAPOPORT, A; STEIN, D; SCHWARTZ, M et al.Journal of neural transmission. 1999, Vol 106, Num 9-10, pp 911-918, issn 0300-9564Article

Regional and molecular separation of the four bioactivities of 'tribulin'HUCKLEBRIDGE, F; DOYLE, A; PANG, F.-Y et al.Neuroscience letters. 1998, Vol 240, Num 1, pp 29-32, issn 0304-3940Article

Pharmacokinetic evaluation of a selegiline pulsatile oral delivery systemROHATAGI, S; BARRETT, J. S; DEWITT, K. E et al.Biopharmaceutics & drug disposition. 1997, Vol 18, Num 8, pp 665-680, issn 0142-2782Article

Time course of physical and psychological responses to selegiline monotherapy in newly diagnosed, idiopathic parkinosonismKIROLLOS, C; CHARLETT, A; DOBBS, R. J et al.European journal of clinical pharmacology. 1996, Vol 50, Num 1-2, pp 7-18, issn 0031-6970Article

Lazabemide, a selective, reversible monoamine oxidase B inhibitor, as an aid to smoking cessationBERLIN, Ivan; AUBIN, Henri-Jean; PEDARRIOSSE, Anne-Marie et al.Addiction (Abingdon. Print). 2002, Vol 97, Num 10, pp 1347-1354, issn 0965-2140, 8 p.Article

Sélégiline = SelegilineLa Revue Prescrire. 1996, Vol 16, Num 164, pp 507-510, issn 0247-7750Article

Docking studies on monoamine oxidase-B inhibitors : Estimation of inhibition constants (K_i) of a series of experimentally tested compoundsTOPRAKCI, Mustafa; YELEKCI, Kemal.Bioorganic & medicinal chemistry letters (Print). 2005, Vol 15, Num 20, pp 4438-4446, issn 0960-894X, 9 p.Article

Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's diseaseJENNER, Peter.Neurology. 2004, Vol 63, Num 7, pp S13-S22, issn 0028-3878, SUP2Article

A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibitionCLARKE, A; JOHNSON, E. S; MALLARD, N et al.Journal of neural transmission. 2003, Vol 110, Num 11, pp 1257-1271, issn 0300-9564, 15 p.Article

Novel neuroprotective anti-Alzheimer drugs with anti-depressant activity derived from the anti-Parkinson drug, rasagiline : Interventions, Part IIIYOUDIM, Moussa B. H; WEINSTOCK, Marta.Mechanisms of ageing and development. 2002, Vol 123, Num 8, pp 1081-1086, issn 0047-6374Conference Paper

Effects of selegiline pretreatment on response to experimental cocaine administrationNEWTON, T. F; KALECHSTEIN, A; BECKSON, M et al.Psychiatry research. 1999, Vol 87, Num 2-3, pp 101-106, issn 0165-1781Article

Integrated pharmacokinetic and metabolic modeling of selegiline and metabolites after transdermal administrationROHATAGI, S; BARRETT, J. S; DEWITT, K. E et al.Biopharmaceutics & drug disposition. 1997, Vol 18, Num 7, pp 567-584, issn 0142-2782Article

Novel transdermal delivery formulation of the monoamine oxidase inhibitor selegiline nearing release for treatment of depressionTHASE, Michael E.The Journal of clinical psychiatry. 2006, Vol 67, Num 4, pp 671-672, issn 0160-6689, 2 p.Article

Adverse effects of dopamine potentiation by long-term treatment with selegilineHOLLAN, Susan; VECSEI, Laszlo; MAGYAR, D. Kalman et al.Movement disorders. 2004, Vol 19, Num 1, pp 107-109, issn 0885-3185, 3 p.Article

The effect of deprenyl washout in patients with long-standing Parkinson's diseaseDJALDETTI, R; ZIV, I; MELAMED, E et al.Journal of neural transmission. 2002, Vol 109, Num 5-6, pp 797-803, issn 0300-9564Article

Single-blind, placebo phase-in trial of two escalating doses of Selegiline in the Chronic Fatigue syndromeNATELSON, B. H; CHEU, J; HILL, N et al.Neuropsychobiology. 1998, Vol 37, Num 3, pp 150-154, issn 0302-282XArticle

Pharmacokinetics and bioequivalence of the main metabolites of selegiline : desmethylselegiline, methamphetamine and amphetamine after oral administration of selegilineMASCHER, H. J; KIKUTA, C; MILLENDORFER, A et al.International journal of clinical pharmacology and therapeutics. 1997, Vol 35, Num 1, pp 9-13, issn 0946-1965Article

Selegiline in ADHD adults : Plasma monoamines and monoamine metabolitesERNST, M; LIEBENAUER, L. L; TEBEKA, D et al.Neuropsychopharmacology (New York, NY). 1997, Vol 16, Num 4, pp 276-284, issn 0893-133XArticle

Effect of treatment with L-deprenyl on age-dependent microanatomical changes in the rat kidneyBATTISTI, A; BARILI, P; FERRANTE, F et al.Mechanisms of ageing and development. 1996, Vol 89, Num 1, pp 1-10, issn 0047-6374Article

Pharmacokinetic-pharmacodynamic interactions between two selective monoamine oxidase inhibitors : Moclobemide and selegilineDINGEMANSE, J; KNEER, J; WALLNÖFER, A et al.Clinical neuropharmacology. 1996, Vol 19, Num 5, pp 399-414, issn 0362-5664Article

Monoamine oxidase inhibitors : An update on drug interactionsLIVINGSTON, M. G; LIVINGSTON, H. M.Drug safety. 1996, Vol 14, Num 4, pp 219-227, issn 0114-5916Article